BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34963839)

  • 1. Efficacy of Cilnidipine (L/N-type Calcium Channel Blocker) in Treatment of Hypertension: A Meta-Analysis of Randomized and Non-randomized Controlled Trials.
    Chakraborty RN; Langade D; More S; Revandkar V; Birla A
    Cureus; 2021 Nov; 13(11):e19822. PubMed ID: 34963839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of combination therapy with an L/N-Type Ca(2+) channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: an observational study conducted in Japan.
    Nagahama S; Norimatsu T; Maki T; Yasuda M; Tanaka S
    Hypertens Res; 2007 Sep; 30(9):815-22. PubMed ID: 18037774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal Function in Hypertensive Patients Receiving Cilnidipine and L-Type Calcium Channel Blockers: A Meta-Analysis of Randomized Controlled and Retrospective Studies.
    Srivathsan M; Vardhan V; Naseem A; Patil S; Rai V; Langade DG
    Cureus; 2022 Aug; 14(8):e27847. PubMed ID: 36110460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cochrane in context: pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
    Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis.
    Seleme VB; Marques GL; Mendes AEM; Rotta I; Pereira M; Júnior EL; da Cunha CLP
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):165-180. PubMed ID: 32710438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparative Study on Clinical and Biochemical Parameters in Amlodipine and Cilnidipine Treated Hypertensive Patients.
    Shetty K; Shetty R; Bairy L; Rao P; Kiran A; Shetty M; Deepak ; Nayak V
    J Clin Diagn Res; 2017 May; 11(5):FC01-FC05. PubMed ID: 28658794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.
    Kanaoka T; Tamura K; Wakui H; Ohsawa M; Azushima K; Uneda K; Kobayashi R; Fujikawa T; Tsurumi-Ikeya Y; Maeda A; Yanagi M; Toya Y; Umemura S
    Int J Mol Sci; 2013 Aug; 14(8):16866-81. PubMed ID: 23959116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium channel blockers for people with chronic kidney disease requiring dialysis.
    Mugendi GA; Mutua FM; Natale P; Esterhuizen TM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011064. PubMed ID: 33000470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
    Hackam DG; Khan NA; Hemmelgarn BR; Rabkin SW; Touyz RM; Campbell NR; Padwal R; Campbell TS; Lindsay MP; Hill MD; Quinn RR; Mahon JL; Herman RJ; Schiffrin EL; Ruzicka M; Larochelle P; Feldman RD; Lebel M; Poirier L; Arnold JM; Moe GW; Howlett JG; Trudeau L; Bacon SL; Petrella RJ; Milot A; Stone JA; Drouin D; Boulanger JM; Sharma M; Hamet P; Fodor G; Dresser GK; Carruthers SG; Pylypchuk G; Burgess ED; Burns KD; Vallée M; Prasad GV; Gilbert RE; Leiter LA; Jones C; Ogilvie RI; Woo V; McFarlane PA; Hegele RA; Tobe SW;
    Can J Cardiol; 2010 May; 26(5):249-58. PubMed ID: 20485689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients.
    Yang Y; Wei RB; Xing Y; Tang L; Zheng XY; Wang ZC; Gao YW; Li MX; Chen XM
    Metabolism; 2013 Dec; 62(12):1858-66. PubMed ID: 24050270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
    Konoshita T; Kaeriyama S; Urabe M; Nakaya T; Yamada M; Ichikawa M; Yamamoto K; Sato S; Imagawa M; Fujii M; Makino Y; Zenimaru Y; Wakahara S; Suzuki J; Ishizuka T; Nakamura H;
    Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27515419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to an L/N-type calcium channel blocker shows renoprotective effects in patients with chronic kidney disease: the Kyoto Cilnidipine Study.
    Hatta T; Takeda K; Shiotsu Y; Sugishita C; Adachi T; Kimura T; Sonomura K; Kusaba T; Kishimioto N; Narumiya H; Tanda S; Tamagaki K; Yamada K; Kameyama H; Kido H; Harada S; Bito Y; Moriguchi J; Morimoto S; Okigaki M; Itoh H; Mori Y; Nakata T; Maki K; Sasaki S; Sawada K; Matsubara H
    J Int Med Res; 2012; 40(4):1417-28. PubMed ID: 22971493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
    Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension.
    Wong GW; Boyda HN; Wright JM
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD007450. PubMed ID: 25427719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.
    Wong GW; Boyda HN; Wright JM
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD007451. PubMed ID: 26961574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE.
    Kario K; Ando S; Kido H; Nariyama J; Takiuchi S; Yagi T; Shimizu T; Eguchi K; Ohno M; Kinoshita O; Yamada T
    J Clin Hypertens (Greenwich); 2013 Feb; 15(2):133-42. PubMed ID: 23339732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilnidipine: Next Generation Calcium Channel Blocker.
    Shete MM
    J Assoc Physicians India; 2016 Apr; 64(4):95-99. PubMed ID: 27734656
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.